Other News To Note

Unigene Laboratories Inc., of Boonton, N.J., and Nordic Bioscience AS, of Copenhagen, Denmark, are establishing a joint development vehicle (JDV) to advance up to three of Unigene's calcitonin analogues through Phase II proof-of-concept trials for the treatment of Type II diabetes, osteoarthritis and osteoporosis. Unigene and Nordic will each own 50 percent of the joint venture.